High-Risk Kids' Vaccine
FDA Approves Merck's CAPVAXIVE for High-Risk Children with Chronic Conditions
Key Points
CAPVAXIVE’s expanded indication specifies prevention of invasive pneumococcal disease and pneumonia due to a defined set of serotypes (for both indications): 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B (for invasive disease) and 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B (for pneumonia).
Merck’s notice includes a safety warning that CAPVAXIVE should not be given to people with a history of severe allergic reaction (e.g., anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid.
Merck infectious-diseases vaccine leader Dr. Paula Annunziato said the vaccine, although originally designed for adults, “addresses a specific unmet need for young patients with high-risk health conditions.”
Merck also said CAPVAXIVE covers serotypes responsible for approximately 79% of invasive pneumococcal disease cases in the studied at-risk pediatric group.
The FDA has approved Merck's CAPVAXIVE vaccine for children and teenagers ages 2 through 17 who have chronic health conditions — making it the only pneumococcal conjugate vaccine in the U.S. specifically studied and indicated for this high-risk group, according to Merck Newsroom. The expanded label covers prevention of invasive pneumococcal disease and pneumonia caused by 21 bacterial strains.
Merck announced the approval on June 18, 2026. The company says CAPVAXIVE covers serotypes responsible for roughly 79% of invasive pneumococcal disease cases in the at-risk pediatric group, based on CDC surveillance data from 2015 to 2019, Benzinga reported.
What CAPVAXIVE Does That Other Vaccines Don't
Standard childhood vaccines like PCV13 and PCV15 protect infants from the most common pneumococcal strains. But "serotype replacement" has happened over time — strains not covered by those vaccines are now causing more infections. CAPVAXIVE fills that gap. It is not a replacement for the primary infant series. It is a supplemental dose given after a child has already finished that series, according to Drug Topics.
The vaccine targets 21 strains, including several that are more common in adults but rising in high-risk children. Dr. Paula Annunziato, Merck's vaccine chief, said CAPVAXIVE "addresses a specific unmet need for young patients with high-risk health conditions." Children with diabetes, chronic heart disease, lung disease, or kidney disease are among those who qualify for the shot.
Phase 3 Trial Data Behind the FDA Decision
The approval rests on Merck's STRIDE-13 trial, which enrolled roughly 874 to 882 children and teenagers with chronic medical conditions. Participants received either CAPVAXIVE or PPSV23, the older polysaccharide vaccine, in a 3-to-2 ratio. CAPVAXIVE showed stronger immune responses across its covered strains, according to Conexiant.
Safety results were reassuring. Serious adverse events occurred in 5.5% of the CAPVAXIVE group and 7.2% of the PPSV23 group within six months. Only one serious adverse event was linked to CAPVAXIVE — a Grade 2 fainting episode three minutes after vaccination, Conexiant reported. Merck first presented these data at a vaccines conference in Lisbon in September 2025.
Pneumonia Approval Comes With a Catch
The FDA granted the pneumonia portion of the label under accelerated approval. That means it is based on immune response data — specifically opsonophagocytic activity, a lab measure of how well the immune system kills bacteria — rather than direct evidence of fewer pneumonia cases in children. Full approval depends on results from a confirmatory trial still underway, according to Pharm Executive.
Dr. Rotem Lapidot, a pediatric infectious disease specialist and STRIDE-13 investigator, noted that children with chronic conditions face "increased risk for pneumonia, meningitis, and bloodstream infections." She called the approval a "new approach" to protecting these patients, as cited by Drug Topics.
Market Edge and What Comes Next for Rivals
Merck now holds a first-mover advantage. No other conjugate vaccine is specifically indicated for this supplemental pediatric use. Financial analysts at Benzinga describe the move as a way to carve out a high-risk niche and differentiate CAPVAXIVE from Pfizer's Prevnar franchise. Merck shares rose modestly after the announcement. The company reported annual revenues of $65.77 billion and a gross profit margin of 76.73%.
The CDC's Advisory Committee on Immunization Practices is expected to review the new indication in upcoming meetings. A positive ACIP vote could add CAPVAXIVE to the Vaccines for Children program, dramatically expanding access. Competitors are also moving fast — Pfizer is testing a 25-valent candidate, and Vaxcyte is developing VAX-31, according to TechTimes.
Sentiment
Mostly PositivePublishers
13
Articles
89
Reach
102
